ROIV
Roivant Sciences Ltd.
September 14, 2026 · after-hours
- Rarity
- 1.07
- Peak move
- −4.36%
- Float cap
- $21.2B
Roivant Sciences Ltd. is a biopharmaceutical company that develops and commercializes medicines for patients with unmet medical needs. It advances a pipeline of investigational therapies, including brepocitinib, IMVT-1402, and mosliciguat, through nimble subsidiaries called Vants. The company also incubates discovery-stage biopharmaceutical and health technology startups complementary to its core business.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
2 events · 0 from SEC or newswire · 0 timed with the moveinsider_saleRoivant Sciences Ltd. disclosed an SEC Form 4 statement of changes in beneficial ownership for filer Meghan Fitzgerald, filed September 14, 2026, covering a transaction dated September 10, 2026.
litigation_outcomeModerna agreed to pay Roivant Sciences up to $2.25 billion to settle claims that its COVID-19 vaccine infringed Roivant's (Genevant's) patents, resolving the patent dispute between the two companies.